Drugs / SARS-CoV-2 rS
SARS-CoV-2 rS
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04961541 | Sep → Dec 2021 | COVID-19 | Novavax | Completed | No outcome recorded |
| Phase 1/2 | NCT04368988 | May 2020 → Jun 2022 | COVID-19 | Novavax | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05515042 Comparator | Jul 2022 → Jun 2024 overdue | COVID-19 | The Aurum Institute NPC | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2022-11-08 | Novavax | Results Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster novavax.com ↗
The data demonstrate that the BA.1 vaccine candidate neutralizing responses in those not previously exposed to COVID-19 were greater than those of the prototype vaccine (NVX-CoV2373), enabling a shift to a new variant vaccine, if necessary (see chart 1). |
| 2022-04-20 | Novavax | Results Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine novavax.com ↗
The preliminary trial results found that various CIC vaccine formulations induced immune responses in participants comparable to reference stand-alone influenza and stand-alone COVID-19 vaccine formulations (for H1N1, H3N2, B-Victoria HA and SARS-CoV-2 rS antigens). |
| 2022-03-22 | Novavax | Regulatory Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to <18 in India novavax.com ↗ |
| 2021-12-22 | Novavax | Results Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies novavax.com ↗
New results demonstrate broad cross-reactivity against Omicron and other circulating variants from a primary 2-dose regimen, with responses that increased following a third dose at six months. |
| 2021-12-20 | Novavax | Regulatory World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine novavax.com ↗
Today's EUL pertains to vaccine to be marketed by Novavax as Nuvaxovid™ COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]) in Europe and other markets. |
| 2021-12-17 | Novavax | Regulatory Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine novavax.com ↗
Today's EUL pertains to vaccine manufactured and marketed by SII as COVOVAX™, a novel recombinant, adjuvanted SARS-CoV-2 rS Vaccine, in India and licensed territories. |
All press releases naming this drug 6 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 rS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04961541 ↗ |
| Known as | CovovaxTM | “SARS-CoV-2 rS (CovovaxTM): is a recombinant protein nanoparticle vaccine constructed from the SARS-CoV-2 full-length spike (S) glycoprotein co-formulated with Matrix-M1 adjuvant.” NCT05515042 ↗ |
| Known as | SARS-CoV-2-rS-PN | “SARS-CoV-2-rS-protein-nanoparticle (SARS-CoV-2-rS-PN). Participants, investigators, and site staff (except for site pharmacists) were masked to participant treatment assignment.” PMID 41690324 ↗ Feb 2026 |
| Known as | SARS-CoV-2-rS-protein-nanoparticle | “SARS-CoV-2-rS-protein-nanoparticle (SARS-CoV-2-rS-PN). Participants, investigators, and site staff (except for site pharmacists) were masked to participant treatment assignment.” PMID 41690324 ↗ Feb 2026 |
| Modality | Vaccine | “SARS-CoV-2 recombinant spike protein vaccine” PMID 35963274 ↗ Aug 2022 |
| Route | Intramuscular | “Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS (0.6 mL) on Days 0 and 21.” NCT04368988 ↗ |